{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:52:34Z","timestamp":1792212754134,"version":"4.4.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Outcomes are poor in patients with higher-risk myelodysplastic syndromes (HR MDS) and frontline treatment options are limited. This phase 1b study investigated safety and efficacy of venetoclax, a selective B-cell lymphoma 2 inhibitor, at the recommended phase 2 dose (RP2D; 400 mg for 14 days per 28-day cycle), in combination with azacitidine (75 mg\/m2 for 7 days per 28-day cycle) for treatment-naive HR MDS. Safety was the primary outcome, and complete remission (CR) rate was the primary efficacy outcome. Secondary outcomes included rates of modified overall response (mOR), hematologic improvement (HI), overall survival (OS), and time to next treatment (TTNT). As of May 2023, 107 patients received venetoclax and azacitidine combination at the RP2D. Best response of CR or marrow CR was observed in 29.9% and 50.5% (mOR, 80.4%), respectively. Median OS was 26.0 months, with 1- and 2-year survival estimates of 71.2% and 51.3%, respectively. Among 59 patients with baseline red blood cell and\/or platelet transfusion\u2013dependence, 24 (40.7%) achieved transfusion independence on study, including 11 (18.6%) in CR. Fifty-one (49.0%) of 104 evaluable patients achieved HI. Median TTNT excluding transplantation was 13.4 months. Adverse events reflected known safety profiles for venetoclax and azacitidine, including constipation (53.3%), nausea (49.5%), neutropenia (48.6%), thrombocytopenia (44.9%), febrile neutropenia (42.1%), and diarrhea (41.1%). Overall, venetoclax plus azacitidine at the RP2D was well tolerated and had favorable outcomes. A phase 3 study (NCT04401748) is ongoing to confirm survival benefit of this combination. This trial was registered at www.clinicaltrials.gov as #NCT02942290.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025464","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:16:42Z","timestamp":1733779002000},"page":"1126-1135","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"2Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, Universit\u00e4tsklinikum Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[{"name":"3Section of Hematology\/Oncology, Department of Medicine, The University of Chicago Medicine and Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[{"name":"4Department of Malignant Haematology and Stem Cell Transplantation, Alfred Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-103X","authenticated-orcid":false,"given":"Chun Yew","family":"Fong","sequence":"additional","affiliation":[{"name":"5Department of Clinical Haematology, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-4962","authenticated-orcid":false,"given":"Uma","family":"Borate","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan A.","family":"Jacoby","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Washington University-School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-7921","authenticated-orcid":false,"given":"Daniel","family":"Nowak","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"9Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"11AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huipei","family":"Wang","sequence":"additional","affiliation":[{"name":"11AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Ku","sequence":"additional","affiliation":[{"name":"12Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hoffman","sequence":"additional","affiliation":[{"name":"11AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[{"name":"11AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"13Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2025031315211783100_bib1","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ajh.25950","article-title":"Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management","volume":"95","author":"Garcia-Manero","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2025031315211783100_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/hematology.2019000042","article-title":"In MDS, is higher risk higher reward?","volume":"2019","author":"Sanz","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2025031315211783100_bib3","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"2025031315211783100_bib4","doi-asserted-by":"crossref","first-page":"106555","DOI":"10.1016\/j.leukres.2021.106555","article-title":"A\u00a0systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival","volume":"104","author":"Garcia","year":"2021","journal-title":"Leuk Res"},{"issue":"8","key":"2025031315211783100_bib5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/genes12081144","article-title":"The genetics of myelodysplastic syndromes: clinical relevance","volume":"12","author":"Chiereghin","year":"2021","journal-title":"Genes"},{"issue":"8","key":"2025031315211783100_bib6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"2025031315211783100_bib7","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2025031315211783100_bib8","first-page":"1513","article-title":"Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches","volume":"91","author":"Deschler","year":"2006","journal-title":"Haematologica"},{"issue":"27","key":"2025031315211783100_bib9","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025031315211783100_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025031315211783100_bib11","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"2025031315211783100_bib12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025031315211783100_bib13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.30533","article-title":"Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes","volume":"123","author":"Garcia-Manero","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"2025031315211783100_bib14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2015.115","article-title":"Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry","volume":"29","author":"Bernal","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2025031315211783100_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.beha.2012.10.007","article-title":"Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?","volume":"25","author":"Steensma","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025031315211783100_bib16","volume-title":"Venclexta (venetoclax). Package insert","year":"2022"},{"key":"2025031315211783100_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-019-0133-1","article-title":"Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose","volume":"8","author":"Jilg","year":"2019","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"2025031315211783100_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"13","key":"2025031315211783100_bib19","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025031315211783100_bib20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"issue":"30","key":"2025031315211783100_bib21","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025031315211783100_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2025031315211783100_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2025031315211783100_bib24","first-page":"30","article-title":"Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases &gt;\/=60 years old","volume":"6","author":"Shima","year":"2023","journal-title":"Blood Cell Ther"},{"issue":"36","key":"2025031315211783100_bib25","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2217\/fon-2022-0334","article-title":"Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes","volume":"18","author":"Kota","year":"2022","journal-title":"Future Oncol"},{"issue":"10","key":"2025031315211783100_bib26","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cncr.21860","article-title":"Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life","volume":"106","author":"Balducci","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2025031315211783100_bib27","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"2025031315211783100_bib28","volume-title":"Vidaza (azacitidine). Package insert","year":"2022"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/11\/1126\/2359259\/blood_bld-2024-025464-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/11\/1126\/2359259\/blood_bld-2024-025464-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:22:56Z","timestamp":1741879376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/11\/1126\/534406\/Efficacy-and-safety-of-venetoclax-plus-azacitidine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025464","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}